BioSpace News Archive

Feb. 7, 2020 13:00 UTC OncoSec Announces that Nevada Court Denies Alpha Holdings’ Motion to Enjoin Special Meeting of Shareholders Court Rules in Favor of OncoSec – Special Meeting of Shareholders Will Proceed as Planned Today SAN DIEGO & PENNINGTON, N.J.--( BUSINESS WIRE )-- OncoSec Medical Incorporated (NASDAQ:ONCS) (the “Company” or “OncoSec”), a company developing late-stage intratumoral cancer immunotherapies, today commented on the February 6 ruling from the Dist

Jeff Needham to retire; Rich Sorota appointed to lead Consumer Self-Care Americas business

Following are the latest Coronavirus news releases and story ideas for reporters, bloggers and media outlets.

Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled Nitric Oxide (NO) for the treatment of patients with respiratory conditions including serious lung infections and pulmonary hypertension, today announced its financial results for its fiscal third quarter ended December 31, 2019.

Aurora Spine Corporation (“Aurora Spine” or the “Company”) (TSX VENTURE:ASG) is pleased to announce that it has closed the final tranche of its non-brokered private placement offering (the “Offering”). Under the final tranche of the Offering, the Company issued 3,432,000 units (the “Units”) at a price of CDN$0.25 per Unit for aggregate gross proceeds of approximately CDN$858,000.

CHARLOTTESVILLE, Va., Feb. 07, 2020 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or “the Company”), a cutting-edge biotechnology company developing new treatments for life-threatening medical conditions by improving the body’s ability to bring oxygen to the areas where it is needed most, today announced that it has been granted Patent Number EP2540696 B1 from the European Patent Office. This patent relates to pharmaceutical compositions of trans sodium croce

PAY DATE: Monday, February 24, 2020 EX DATE: Tuesday, February 25, 2020 MIRAMAR, Fla., Feb. 07, 2020 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation ( www.generex.com ) (OTCQB:GNBT) (“Generex”) is pleased to announce the successful completion of the FINRA review process for the dividend. After an exhaustive and long review, FINRA has determined that the original August 30 record date is too long ago to adequately track all the pay due bills from stock being bought and sold by investors

HOUSTON, Feb. 07, 2020 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage oncology company targeting the epigenetic causes of cancer, today announced the pricing of an underwritten public offering for gross proceeds of approximately $9.6 million, prior to deducting underwriting discounts and commissions and offering expenses payable by Salarius. The offering is comprised of 7,101,307 Class A Units, priced at a public offering price of $1.15 per unit, with eac

With the increasing incidence of Alzheimer’s disease and dementia, affected families are all too often “stretched to the breaking point,” according to Kara Bonela, Vice President, Marketing, Alzheimer’s Los Angeles.

NEW YORK, Feb. 07, 2020 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, announced today the pricing of an underwritten public offering with expected total gross proceeds of $7.5 million before deducting underwriting discounts, commissions and other offering expenses payable by the Company. The securities offered by the Company consist of (i) 3,837,000 Class A Units, each Class A Unit consisting of one